MD Anderson's Lymphoma and Myeloma Center is at the forefront of discovering new, more-effective multiple myeloma therapies. We're also leading the way toward advances in lowering the impact of the disease and its treatment on the body.
Many times, treatment for multiple myeloma may continue for extended periods, with repeated remissions and recurrences. For this reason, our teams of experts, including specially trained support professionals, forge close medical relationships with you to be sure you receive personal, customized care. This individualized attention gives you the best chance of a full and healthy life.
MD Anderson has been instrumental in some of the biggest advances in multiple myeloma treatment, including Revlimid® (lenalidomide), a derivative of thalidomide. It is one of the most important discoveries in multiple myeloma therapy in recent years. We've also found that combining this drug with chemotherapy drugs often has a profound effect on multiple myeloma, even after other treatments have failed.
At MD Anderson, you benefit from one of the most active research programs in the United States, which includes a prestigious federally funded SPORE (Specialized Program of Research Excellence) program. This means we are able to offer a wide range of clinical trials (research studies) for every stage of multiple myeloma.
Whether you have just been diagnosed with multiple myeloma or have been battling it for a while, we're here to help.Call 1-877-MDA-6789 to make an appointment or request an appointment online.
Why Choose MD Anderson?
- Personalized multiple myeloma treatments, including vaccine and cytokine therapies, monoclonal antibodies and liposomal drug delivery
- Genetic testing to pinpoint myeloma, increase likelihood of successful treatment
- Advanced myeloma treatments with least impact on your body
- One of the largest teams of experts focused on myeloma
- Nationally recognized research program offers clinical trials of new therapies
Multiple Myeloma Knowledge Center
Multiple Myeloma Facts
Multiple myeloma is uncommon. According to the National Cancer Institute, it affects about 21,000 people each year in the United States.
Although its exact cause is unknown, multiple myeloma can be controlled in most patients, sometimes for many years. The development of new drugs – many here at MD Anderson – has helped manage multiple myeloma in a larger number of patients and has resulted in longer average times of survival.
What is Multiple Myeloma?
Multiple myeloma is a type of blood cancer that affects the bone marrow, the body's blood-forming system. In this disease, the plasma cells (a type of white blood cell) become abnormal and multiply rapidly. This causes them to interfere with the production of normal blood cells.
The plasma cells make an abnormal protein that is sent into the blood and urine. In the blood, these proteins are called monoclonal proteins (M proteins) or paraproteins. In the urine, they are called Bence Jones proteins.
If these proteins build up in large amounts, the kidneys may have trouble processing all of the protein. This may cause the kidneys to stop working as well as they should. Multiple myeloma cells also can eat away at areas of bone, putting these bones at higher risk of fracture.
If you have been diagnosed with multiple myeloma or the disease has returned, we’re here to help. Call 1-877-MDA-6789 to make an appointment or request an appointment online.